In prostate cancer models, pharmacological inhibition of YAP1 was shown to induce phenotypic switching of CAFs from tumor‐promoting to tumor‐suppressive states, consequently enhancing the responsiveness of prostate tumors to immune checkpoint blockade (ICB) therapy [42]. The gene discussed is YAP1; the disease is prostate carcinoma.